Between 20 and 30 percent of people with psoriasis develop a second condition: psoriatic arthritis, where joints become inflamed and painful. For decades, doctors knew this progression happened — they just didn't know why it happened to some patients and not others. A team of German researchers has now found the answer, and it opens a path to stopping the disease before it reaches the joints.
The story starts in the skin. When psoriasis develops, the immune system goes into overdrive, creating specialized inflammatory cells in the affected areas. These cells don't stay put. "These cells can migrate from the skin to the bloodstream and from there to the joints," explains Dr. Simon Rauber, who led the research. But here's the crucial part: simply arriving in the joint isn't enough to cause arthritis. Something else has to fail.
That something is the joint's own defense system. When inflammatory cells infiltrate a healthy joint, connective tissue cells called fibroblasts normally act as bouncers — they contain the inflammation and keep it from spiraling. In people who develop psoriatic arthritis, this protective function breaks down. "The inflammatory cells that enter the joint cannot be brought into check, and go on to trigger an inflammatory reaction," says Prof. Dr. Andreas Ramming, another lead researcher.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxSo the progression depends on two things happening: inflammatory cells traveling from skin to joint, and the joint's natural defense system failing to stop them. Understanding this two-step process changes everything about prevention.
The researchers found that these migratory immune cells show up in the bloodstream before they ever reach the joints — sometimes well before symptoms appear. That gap is a window. If doctors can identify patients with these traveling cells early, they could potentially intercept them before they settle in the joints and trigger arthritis. Instead of treating arthritis after it develops, treatment could shift to prevention.
The research, published in Nature Immunology and funded by the German Research Foundation and European Research Council, suggests that future therapies might focus on either stopping these cells from migrating or strengthening the joint's protective response. For the roughly 1.5 million Americans with psoriasis, the possibility of preventing arthritis before it starts could mean the difference between manageable skin symptoms and years of joint pain.
